尊敬的各位BI用戶：
LETTER TO BI CUSTOMERS
大家好！
Greetings!
2019年12月，德國賽多利斯（Sartorius）與以色列Biological Industries（BI）簽署合作協(xié)議，收購BI公司多數(shù)股權(quán)（詳情請查看鏈接：https://www.sartorius.com/en/company/newsroom/corporate-news/370526-370526）。BI中國區(qū)業(yè)務(wù)將進行調(diào)整，調(diào)整如下：
In Dec. 2019, Sartorius（Germany）and Biological Industries, Israel（BI） had signed an agreement in acquiring major shares of Biological Industries（See link above）. The business structure in China will be adjusted as follows：
1. 血清系列產(chǎn)品
Serum Product Line
BI公司將停止在中國銷售其品牌下動物血清系列產(chǎn)品，轉(zhuǎn)交由上海逍鵬生物科技有限公司VivaCell品牌繼續(xù)銷售，保證原有產(chǎn)品質(zhì)量，并一如既往地承擔技術(shù)與客戶服務(wù)業(yè)務(wù)。
BI will stop all animal serum business in China, all related business will be transferred to Shanghai XP Biomed Ltd.（XP）and operate under VivaCell（VC）brand name. VC will guarantee original product quality and providing same technical support and customer service.
2. 其他系列產(chǎn)品
Other BI business
如：無血清培養(yǎng)基（干細胞、免疫細胞、Vero等）、基礎(chǔ)培養(yǎng)基、細胞輔助試劑（胰酶、凍存液、支原體相關(guān)試劑）等，將維持原品牌與銷售渠道。
Such as Serum Free Medium（NutriStem? series, Immuno cell, Vero etc.）, Basal Medium, Ancillary Materials（Trypsin, freezing solution, mycoplasma related reagents）etc, will remain under same BI brand and sales channel.
逍鵬生物仍為BI在中國區(qū)域（含香港、澳門區(qū)域）的代理商，代理權(quán)限不變（詳情查看鏈接：https://www.bioind.com/worldwide/distributors/），繼續(xù)負責執(zhí)行原本工作職能，提供市場推廣、知識培訓、技術(shù)支持及客戶售前售后服務(wù)。
XP is still BI's agent in China（Including Hong Kong and Macao）, and the agency authority remains unchanged （See link above）.Operated continuously by Shanghai XP Biomed Ltd. XP will carry on its original function, providing marketing promotion, education training, technical support and pre/after sales services.
上海逍鵬生物科技有限公司
Shanghai XP Biomed Ltd
2021年01月11日
